Skip to main content

Table 3 Number of doses received during each cycle of HD IL-2

From: A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

Cycle Group n Mean Min Max
1 Prior Ipi 52 9.9 3 14
No ICB 276 9.9 1 14
2 Prior Ipi 49 8.2 1 14
No ICB 252 8.2 2 14
3 Prior Ipi 17 8.2 5 12
No ICB 98 8.6 1 14
4 Prior Ipi 17 6.7 2 12
No ICB 88 6.6 2 14